Revenue
2011
2012
2013
2014
2015
2016
2022
2023
2024
2025
Tenax Therapeutics, Inc. (TENX)
Price$1.86Cached quote
Net income
2011
2012
2013
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 · Dec 31 | 2015 · Apr 30 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | $0 | — | $49,286 | $158,926 | $1.2M | $363,781 | $103,167 |
| Gross profit | — | — | — | — | — | — | — | — | — | $0 | — | $0 | −$104,069 | $49,572 | $49,266 | $103,167 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | 0.00% | −65.48% | 4.16% | 13.54% | 100.00% |
| Research & development | $32.7M | $12.7M | $3.2M | $5.4M | $25.1M | $4.6M | $3.5M | $1.2M | $3.5M | $13.1M | $6.5M | $6.7M | $3.0M | $2.5M | $2.5M | $2.7M |
| Operating expenses | $56.4M | $19.5M | $8.2M | $11.1M | $32.7M | $9.9M | $8.6M | $6.9M | $9.2M | $52.7M | $10.4M | $14.9M | $16.8M | $6.4M | $8.6M | $10.7M |
| Operating income | −$56.4M | −$19.5M | −$8.2M | $11.1M | −$32.7M | $9.9M | −$8.6M | −$6.9M | −$9.2M | −$52.7M | −$10.4M | −$14.8M | −$16.6M | −$5.2M | −$8.2M | $10.6M |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | −30,062.78% | −10,452.11% | −435.71% | −2,259.66% | 10,238.43% |
| EBITDA | −$52.6M | −$19.5M | −$8.2M | $11.1M | −$32.7M | $9.9M | −$8.6M | −$6.9M | −$9.2M | −$52.6M | −$10.4M | −$14.7M | −$16.5M | −$5.0M | −$8.0M | $10.9M |
| EBITDA margin | — | — | — | — | — | — | — | — | — | — | — | −29,762.21% | −10,357.42% | −423.22% | −2,202.84% | 10,539.90% |
| Net income | −$52.6M | −$17.6M | −$7.7M | $11.0M | −$32.5M | −$9.9M | −$8.4M | −$14.1M | −$8.8M | −$43.9M | −$10.1M | −$14.1M | −$19.5M | −$9.4M | −$15.7M | $10.4M |
| Net profit margin | — | — | — | — | — | — | — | — | — | — | — | −28,571.63% | −12,296.19% | −790.63% | −4,319.19% | 10,127.56% |
| Basic EPSper basic share | -$1.34 | -$1.15 | -$31.04 | -$600.71 | -$2,528.00 | -$1,520.00 | -$2,160.00 | -$14,464.00 | -$10,032.00 | -$49,984.00 | -$11,520.00 | -$16,000.00 | -$86,720.00 | -$201,280.00 | -$387,840.00 | -$288,000.00 |
| Diluted EPSper diluted share | -$1.34 | -$1.15 | -$31.04 | -$600.71 | -$2,528.00 | -$1,520.00 | -$2,160.00 | -$14,464.00 | -$10,032.00 | -$49,984.00 | -$11,520.00 | -$16,000.00 | -$86,720.00 | -$213,760.00 | -$450,240.00 | -$288,000.00 |
Owners
Reported shareholders
12.34%of listed shares
FMR LLC3.94M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 12.34%3.94M shares |
Vivo Capital, LLC | 7.82%2.5M shares |
BlackRock, Inc. | 5.41%1.73M shares |
PERCEPTIVE ADVISORS LLC | 5.32%1.7M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.59%1.15M shares |
MILLENNIUM MANAGEMENT LLC | 2.74%876.23K shares |
Ikarian Capital, LLC | 2.47%787.6K shares |
Candriam S.C.A. | 2.35%749.59K shares |
CITADEL ADVISORS LLC | 2.28%728.56K shares |
RTW INVESTMENTS, LP | 2.18%696.57K shares |
Stonepine Capital Management, LLC | 2.07%660K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.00%639.54K shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.90%607.66K shares |
MARSHALL WACE, LLP | 1.83%585.58K shares |
BRAIDWELL LP | 1.83%584.41K shares |
Point72 Asset Management, L.P. | 1.74%556.76K shares |
Velan Capital Investment Management LP | 1.72%549.99K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.69%540.13K shares |
Woodline Partners LP | 1.66%531.25K shares |
STATE STREET CORP | 1.60%510.81K shares |
Percentages use 31.95M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 9, 2025Form 4 | Rich StuartChief Medical Officer | BuyCommon Stock | 2.5K | $10.22 | $25.6K | 5.3K |
| Dec 8, 2025Form 4 | Rich StuartChief Medical Officer | BuyCommon Stock · indirect | 2.5K | $10.10 | $25.3K | 5.0K |
| Dec 4, 2025Form 4 | Rich StuartChief Medical Officer | BuyCommon Stock · indirect | 2.5K | $9.20 | $23.0K | 2.5K |
| Dec 3, 2025Form 4 | Rich StuartChief Medical Officer | BuyCommon Stock | 1.5K | $9.08 | $13.6K | 2.8K |
| Dec 2, 2025Form 4 | Rich StuartChief Medical Officer | BuyCommon Stock | 1.0K | $9.01 | $9.0K | 1.3K |